PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Telmisartan - Hypertension

PAD Profile : Telmisartan - Hypertension

Keywords :
ARBs, high blood pressure, raised blood pressure
Brand Names Include :
Micardis

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 September 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the 1st line use of Angiotensin Receptor Blockers (ARBs) instead of an Angiotensin Converting Enzyme (ACE) inhibitor, for adults with hypertension where the use of an ARB or ACE is deemed equally appropriate.

Losartan or candesartan - 1st line

Alternative options:
Irebsartan - Green
Telmisartan - Green
Valsartan - Green
Olmesartan - Green

Azlisartan - do not initiate in new patients
Eprosartan - do not initiate in new patients

Local hypertension guidelines / pathways will be reviewed and updated in light of this decision

03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC telmisartan has been considered by the PCN and has been assigned a GREEN traffic light status. NOTE - the branded product, Micardis, was considered BLACK at the PCN in May 2017.

Associated BNF Codes

02. Cardiovascular System
02.05.05. Renin-angiotensin system drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More